Multicentric assessment of empagliflozin, sitagliptin and cholestyramine on n-2 streptozotocin diabe tic rats
Abstract
Diabetes mellitus stands as a major global epidemic, rapidly spreading across the world.WHO reports a continuous and concerning upsurge in both the number of cases and prevalence.In India alone, diabetes prevalence escalated from 7.1% in 2009 to 8.9% in 2019.This research endeavor aimed to investigate the combined effects of three distinct classes of medications; empagliflozin, sitagliptin, and cholestyramine on countering type 2 diabetes induced by streptozotocin (STZ) in neonatal rat pups.The assessment encompassed individual drug therapies as well as their triple combination and evaluated in vitro measurements of -amylase and glucosidase activities.Encouraging results were observed with the triple drug combination in diabetic treatment.The study employed neonatal albino rat pups of both genders, administering a single intraperitonial dose of 90 mg/kg of the potent diabetes-inducing agent streptozotocin.This treatment regimen spanned 4 weeks, after which the animals were anesthetized, and blood, liver, pancreas and kidney samples were collected for antioxidants, histopathological and biochemical analysis.The findings indicated that the triple drug combination exhibited the most favorable outcomes, displaying significant levels (p<0.05),(p<0.01),(p<0.001) against STZ induced type 2 diabetes in neonatal rat pups.Consequently, the study concludes that triple therapy demonstrates synergistic effects in mitigating type 2 diabetes in neonatal rat pups.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.